 BALTIMORE, Sept. 28, 2021 GLOBE NEWSWIRE -- Graybug Vision, Inc. Nasdaq: GRAY, a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration wet AMD, Graybugs proprietary formulation of sunitinib malate injected twice-a-year intravitreally. 